DDInter1837 DDInter596
Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Toremifene {u} may lead to a major life threatening interaction when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Toremifene {u} may lead to a major life threatening interaction when taken with {v} Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Toremifene {u} (Compound) treats {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Doxorubicin
Toremifene {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Toremifene {u} (Compound) upregulates {v} (Gene) DHCR7
DHCR7 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Toremifene {u} (Compound) upregulates {v} (Gene) TCTN1
TCTN1 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Toremifene {u} (Compound) downregulates {v} (Gene) JMJD6
JMJD6 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Toremifene {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Toremifene {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Toremifene {u} may lead to a major life threatening interaction when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Valrubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Toremifene may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Toremifene may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin (Compound) resembles Doxorubicin (Compound)
Toremifene (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Doxorubicin (Compound)
Toremifene (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxorubicin (Compound)
Toremifene (Compound) upregulates DHCR7 (Gene) and DHCR7 (Gene) is bound by Doxorubicin (Compound)
Toremifene (Compound) upregulates TCTN1 (Gene) and TCTN1 (Gene) is upregulated by Doxorubicin (Compound)
Toremifene (Compound) downregulates JMJD6 (Gene) and JMJD6 (Gene) is downregulated by Doxorubicin (Compound)
Toremifene (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is downregulated by Doxorubicin (Compound)
Toremifene (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Doxorubicin (Compound)
Toremifene may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin (Compound) resembles Valrubicin (Compound) and Valrubicin (Compound) resembles Doxorubicin (Compound)